515 related articles for article (PubMed ID: 31359276)
21. Impact of Neoadjuvant Versus Adjuvant Chemotherapy on the Extent of Axillary Surgery for Clinically Node-Negative Breast Cancers of Triple-Negative and HER2-Overexpressing Phenotypes.
Thompson JL; Wrubel E; Davis AT; Koehler T; Chung MH; Wright GP
Clin Breast Cancer; 2020 Oct; 20(5):390-394. PubMed ID: 32444317
[TBL] [Abstract][Full Text] [Related]
22. Locoregional outcomes in clinical stage IIB breast cancer after neoadjuvant therapy and mastectomy with or without radiation.
Diaz DA; Hurley J; Reis I; Takita C; Zhao W; Wright J
Medicine (Baltimore); 2014 Dec; 93(29):e230. PubMed ID: 25546661
[TBL] [Abstract][Full Text] [Related]
23. Multidisciplinary Management of the Axilla in Patients with cT1-T2 N0 Breast Cancer Undergoing Primary Mastectomy: Results from a Prospective Single-Institution Series.
Grossmith S; Nguyen A; Hu J; Plichta JK; Nakhlis F; Cutone L; Dominici L; Golshan M; Duggan M; Carter K; Rhei E; Barbie T; Calvillo K; Nimbkar S; Bellon J; Wong J; Punglia R; Barry W; King TA
Ann Surg Oncol; 2018 Nov; 25(12):3527-3534. PubMed ID: 29868979
[TBL] [Abstract][Full Text] [Related]
24. Impact of Neoadjuvant Chemotherapy on Nodal Disease and Nodal Surgery by Tumor Subtype.
Al-Hilli Z; Hoskin TL; Day CN; Habermann EB; Boughey JC
Ann Surg Oncol; 2018 Feb; 25(2):482-493. PubMed ID: 29181679
[TBL] [Abstract][Full Text] [Related]
25. The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy.
Straver ME; Rutgers EJ; Rodenhuis S; Linn SC; Loo CE; Wesseling J; Russell NS; Oldenburg HS; Antonini N; Vrancken Peeters MT
Ann Surg Oncol; 2010 Sep; 17(9):2411-8. PubMed ID: 20373039
[TBL] [Abstract][Full Text] [Related]
26. Sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with cytologically proven node-positive breast cancer at diagnosis.
Park S; Park JM; Cho JH; Park HS; Kim SI; Park BW
Ann Surg Oncol; 2013 Sep; 20(9):2858-65. PubMed ID: 23645483
[TBL] [Abstract][Full Text] [Related]
27. A Dutch Prediction Tool to Assess the Risk of Additional Axillary Non-Sentinel Lymph Node Involvement in Sentinel Node-Positive Breast Cancer Patients.
van den Hoven I; van Klaveren D; Voogd AC; Vergouwe Y; Tjan-Heijnen V; Roumen RM
Clin Breast Cancer; 2016 Apr; 16(2):123-30. PubMed ID: 26602438
[TBL] [Abstract][Full Text] [Related]
28. Are there changes in characteristics and therapy of young patients with early-onset breast cancer in Germany over the last decade?
Banz-Jansen C; Heinrichs A; Hedderich M; Waldmann A; Wedel B; Mebes I; Diedrich K; Rody A; Fischer D
Arch Gynecol Obstet; 2013 Aug; 288(2):379-83. PubMed ID: 23407999
[TBL] [Abstract][Full Text] [Related]
29. Identification and Resection of Clipped Node Decreases the False-negative Rate of Sentinel Lymph Node Surgery in Patients Presenting With Node-positive Breast Cancer (T0-T4, N1-N2) Who Receive Neoadjuvant Chemotherapy: Results From ACOSOG Z1071 (Alliance).
Boughey JC; Ballman KV; Le-Petross HT; McCall LM; Mittendorf EA; Ahrendt GM; Wilke LG; Taback B; Feliberti EC; Hunt KK
Ann Surg; 2016 Apr; 263(4):802-7. PubMed ID: 26649589
[TBL] [Abstract][Full Text] [Related]
30. Axillary Staging After Neoadjuvant Chemotherapy for Breast Cancer: A Pilot Study Combining Sentinel Lymph Node Biopsy with Radioactive Seed Localization of Pre-treatment Positive Axillary Lymph Nodes.
Diego EJ; McAuliffe PF; Soran A; McGuire KP; Johnson RR; Bonaventura M; Ahrendt GM
Ann Surg Oncol; 2016 May; 23(5):1549-53. PubMed ID: 26727919
[TBL] [Abstract][Full Text] [Related]
31. The role for sentinel lymph node dissection after neoadjuvant chemotherapy in patients who present with node-positive breast cancer.
Alvarado R; Yi M; Le-Petross H; Gilcrease M; Mittendorf EA; Bedrosian I; Hwang RF; Caudle AS; Babiera GV; Akins JS; Kuerer HM; Hunt KK
Ann Surg Oncol; 2012 Oct; 19(10):3177-84. PubMed ID: 22772869
[TBL] [Abstract][Full Text] [Related]
32. The effect of internal mammary lymph node biopsy on the therapeutic decision and survival of patients with breast cancer.
Ozmen V; Ozcinar B; Bozdogan A; Eralp Y; Yavuz E; Dincer M
Eur J Surg Oncol; 2015 Oct; 41(10):1368-72. PubMed ID: 26210653
[TBL] [Abstract][Full Text] [Related]
33. Patterns in the Use of Axillary Operations for Patients with Node-Positive Breast Cancer After Neoadjuvant Chemotherapy: A National Cancer Database (NCDB) Analysis.
Srour MK; Tseng J; Luu M; Alban RF; Giuliano AE; Chung A
Ann Surg Oncol; 2019 Oct; 26(10):3305-3311. PubMed ID: 31342364
[TBL] [Abstract][Full Text] [Related]
34. Association of estrogen receptor, progesterone receptor and HER2 following neoadjuvant systemic treatment in breast cancer patients undergoing surgery.
Tsai YM; Hsu HM; Chen CJ; Hsu KF; Fan HL; Chang H; Chan DC; Yu JC
Ir J Med Sci; 2014 Mar; 183(1):71-5. PubMed ID: 23757214
[TBL] [Abstract][Full Text] [Related]
35. Axillary lymph node recurrence after sentinel lymph node biopsy performed using a combination of indocyanine green fluorescence and the blue dye method in early breast cancer.
Inoue T; Nishi T; Nakano Y; Nishimae A; Sawai Y; Yamasaki M; Inaji H
Breast Cancer; 2016 Mar; 23(2):295-300. PubMed ID: 25348937
[TBL] [Abstract][Full Text] [Related]
36. Staged sentinel lymph node biopsy before mastectomy facilitates surgical planning for breast cancer patients.
Klauber-Demore N; Calvo BF; Hultman CS; Kim HJ; Meyers MO; Damitz L; Frank JS; Stitzenberg KB; Sartor CI; Ollila DW
Am J Surg; 2005 Oct; 190(4):595-7. PubMed ID: 16164929
[TBL] [Abstract][Full Text] [Related]
37. Are there patients with T1 to T2, lymph node-negative breast cancer who are "high-risk" for locoregional disease recurrence?
Mamtani A; Patil S; Stempel MM; Morrow M
Cancer; 2017 Jul; 123(14):2626-2633. PubMed ID: 28334423
[TBL] [Abstract][Full Text] [Related]
38. Discrepancies Between Pathological Tumor Responses and Estimations of Complete Response by Magnetic Resonance Imaging After Neoadjuvant Chemotherapy Differ by Breast Cancer Subtype.
Namura M; Tsunoda H; Yagata H; Hayashi N; Yoshida A; Morishita E; Takei J; Suzuki K; Yamauchi H
Clin Breast Cancer; 2018 Apr; 18(2):128-134. PubMed ID: 28843513
[TBL] [Abstract][Full Text] [Related]
39. Axillary recurrence rate in breast cancer patients with negative sentinel lymph node (SLN) or SLN micrometastases: prospective analysis of 150 patients after SLN biopsy.
Langer I; Marti WR; Guller U; Moch H; Harder F; Oertli D; Zuber M
Ann Surg; 2005 Jan; 241(1):152-8. PubMed ID: 15622003
[TBL] [Abstract][Full Text] [Related]
40. Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status.
Tanioka M; Sasaki M; Shimomura A; Fujishima M; Doi M; Matsuura K; Sakuma T; Yoshimura K; Saeki T; Ohara M; Tsurutani J; Watatani M; Takano T; Kawabata H; Mukai H; Naito Y; Hirokaga K; Takao S; Minami H
Breast; 2014 Aug; 23(4):466-72. PubMed ID: 24742606
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
